Evidence map›Paper›PMID 38002257›Full record

ArticleBiomolecules2023

8-Hydroxydaidzein Induces Apoptosis and Inhibits AML-Associated Gene Expression in U-937 Cells: Potential Phytochemical for AML Treatment.

Pei-Shan Wu, Chih-Yang Wang, Hao-Jen Hsu, Jui-Hung Yen, Ming-Jiuan Wu

Open access · goldAbstract read
In one paragraph

Article in Biomolecules, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.5field-weighted citation impact, top 32% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 3 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 3 institutions in 1 country.

Pei-Shan WuDepartment of Pharmacy, Chia Nan University of Pharmacy and Science, Tainan 717301, Taiwan.
Chih-Yang WangPh.D. Program for Cancer Molecular Biology and Drug Discovery, Taipei Medical University, Taipei 110301, Taiwan.ORCID 0000-0002-4137-5074
Hao-Jen HsuDepartment of Biomedical Sciences and Engineering, Tzu Chi University, Hualien 970, Taiwan.ORCID 0000-0001-6096-7481
Jui-Hung YenDepartment of Molecular Biology and Human Genetics, Tzu Chi University, Hualien 970374, Taiwan.ORCID 0000-0003-2551-350X
Ming-Jiuan WuDepartment of Pharmacy, Chia Nan University of Pharmacy and Science, Tainan 717301, Taiwan.
Chia Nan University of Pharmacy and Science · TWTzu Chi University · TWTaipei Medical University · TW

Funding

National Science and Technology Council, Taiwan NSTC 110-2320-B-041-002-MY3
6 · The paper itself

Abstract

background8-hydroxydaidzein (8-OHD) is a compound derived from daidzein, known for its anti-inflammatory and anti-proliferative properties in K562 human chronic myeloid leukemia (CML) cells. However, its effects on acute myeloid leukemia (AML) cells have not been fully understood.

methodTo investigate its potential anti-AML mechanism, we employed an integrated in vitro-in silico approach.

resultsOur findings demonstrate that 8-OHD suppresses the expression of CDK6 and CCND2 proteins and induces cell apoptosis in U-937 cells by activating Caspase-7 and cleaving PARP-1. Microarray analysis revealed that 8-OHD downregulates differentially expressed genes (DEGs) associated with rRNA processing and ribosome biogenesis pathways. Moreover, AML-target genes, including

conclusionsOverall, this study provides insights into the therapeutic applications of 8-OHD in treating AML and elucidates its underlying mechanisms of action.

Indexed as

ApoptosisLeukemia, Myeloid, AcuteCell Line, TumorCytarabineGene ExpressionHumansIsoflavonesMolecular Docking Simulation8-hydroxydaidzeinCytarabineIsoflavones8-hydroxydaidzeinacute myeloid leukemiaapoptosiscaspase-7CDK6

Identifiers

PMID38002257
PMCPMC10669020
OpenAlexW4388200612

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.